6月29日，Liquidia Technologies盘前上涨5.96%，报80.97美元/股，成交额5.01万美元。
消息面上，公司核心产品YUTREPIA商业化持续放量，一季度净产品销售额约1.3亿美元，超4500份独立患者处方，同比实现扭亏为盈（EPS 0.52美元，远超市场预期的0.41美元）。此外，公司于6月11日宣布将在PHA 2026国际肺动脉高压大会上发布海报数据，学术会议催化叠加业绩高增长预期，持续推升市场情绪。一季度业绩公布后，多家分析师上调目标价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.